UBS: Sands China (01928) fourth quarter EBITDA below expectations, rating remains "Neutral"
The management pointed out that the per capita consumption of the basic midfield sector has remained stagnant, and the inclination towards the high-end sector may affect its profit margin structure.
UBS released a research report stating that Las Vegas Sands (LVS) announced that the adjusted EBITDA for the fourth quarter of 2025 in Macau is $608 million, an increase of about 6% year-on-year. Adjusting for VIP room betting rates, the EBITDA is $582 million, lower than the market consensus forecast of $628 million. The bank rated Sands China (01928) as "neutral" with a target price of HK$22.4.
UBS stated that the profit margin in this quarter is lower than expected, mainly reflecting an increase in costs and a shift in revenue structure towards lower-margin high-end segments. Management reiterated its target of achieving annual EBITDA of $2.7 billion for the Macau property, which the bank believes will be supported by improvements in asset utilization.
Management believes that improvements in marketing plans and the launch of new facilities since the second quarter have led to growth in gaming revenue in the right direction, and will focus on optimizing promotional efficiency in 2026.
Management pointed out that the average consumption per capita in the mass market segment remains stagnant, and the shift towards the high-end segment may impact its profit margin structure.
Related Articles

New stock news: Tian and He Xing submit the Hong Kong Exchange.

New Stock News | Easy Buy Goods Submitting Documents to Hong Kong Stock Exchange

CITIC SEC: The peak of capital outflow is over, the value of bank stock allocation is steadily rising.
New stock news: Tian and He Xing submit the Hong Kong Exchange.

New Stock News | Easy Buy Goods Submitting Documents to Hong Kong Stock Exchange

CITIC SEC: The peak of capital outflow is over, the value of bank stock allocation is steadily rising.

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


